4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide

Identification

Name
4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
Accession Number
DB01888  (EXPT01046)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 471.619
Monoisotopic: 471.241644025
Chemical Formula
C23H33N7O2S
InChI Key
MDIWBYRNTPTYQI-QAQDUYKDSA-N
InChI
InChI=1S/C23H33N7O2S/c1-15(2)20-14-25-30-22(27-18-9-11-19(12-10-18)33(31,32)29(3)4)13-21(28-23(20)30)26-17-7-5-16(24)6-8-17/h9-17,27H,5-8,24H2,1-4H3,(H,26,28)/t16-,17-
IUPAC Name
N,N-dimethyl-4-{[3-(propan-2-yl)-5-{[(1r,4r)-4-aminocyclohexyl]amino}pyrazolo[1,5-a]pyrimidin-7-yl]amino}benzene-1-sulfonamide
SMILES
CC(C)C1=C2N=C(N[[email protected]]3CC[[email protected]](N)CC3)C=C(NC3=CC=C(C=C3)S(=O)(=O)N(C)C)N2N=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UCyclin-dependent kinase 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5287990
PubChem Substance
46505465
BindingDB
11428
ChEMBL
CHEMBL361348
HET
CT9
PDB Entries
1y91

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00934 mg/mLALOGPS
logP3.03ALOGPS
logP2.85ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)17.55ChemAxon
pKa (Strongest Basic)10.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area117.65 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity142.5 m3·mol-1ChemAxon
Polarizability53.04 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7858
Caco-2 permeable-0.6066
P-glycoprotein substrateSubstrate0.5241
P-glycoprotein inhibitor INon-inhibitor0.6774
P-glycoprotein inhibitor IINon-inhibitor0.7318
Renal organic cation transporterNon-inhibitor0.7874
CYP450 2C9 substrateNon-substrate0.7689
CYP450 2D6 substrateNon-substrate0.7739
CYP450 3A4 substrateNon-substrate0.5331
CYP450 1A2 substrateNon-inhibitor0.561
CYP450 2C9 inhibitorNon-inhibitor0.6788
CYP450 2D6 inhibitorNon-inhibitor0.8843
CYP450 2C19 inhibitorNon-inhibitor0.7095
CYP450 3A4 inhibitorNon-inhibitor0.7029
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6644
Ames testNon AMES toxic0.643
CarcinogenicityNon-carcinogens0.8576
BiodegradationNot ready biodegradable0.9952
Rat acute toxicity2.6040 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8199
hERG inhibition (predictor II)Non-inhibitor0.5852
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Pyrazolo[1,5-a]pyrimidines / Benzenesulfonyl compounds / Aniline and substituted anilines / Secondary alkylarylamines / Aminopyrimidines and derivatives / Cyclohexylamines / Organosulfonamides / Imidolactams / Heteroaromatic compounds / Pyrazoles
show 6 more
Substituents
Benzenesulfonamide / Pyrazolo[1,5-a]pyrimidine / Pyrazolopyrimidine / Benzenesulfonyl group / Aniline or substituted anilines / Aminopyrimidine / Cyclohexylamine / Secondary aliphatic/aromatic amine / Pyrimidine / Organosulfonic acid amide
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Details
1. Cyclin-dependent kinase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...
Gene Name
CDK2
Uniprot ID
P24941
Uniprot Name
Cyclin-dependent kinase 2
Molecular Weight
33929.215 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 14:50